Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience

Nephrology

Volumn 17, Issue 8, 2012, Pages 676-680

  Yap, Desmond Yh ^a   Ma, Maggie Km ^a   Tang, Colin So ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

everolimus; lupus nephritis; mammalian target of rapamycin; proliferation signal inhibitor; sirolimus

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION;

ADRENAL CORTEX HORMONES; ADULT; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84868138682     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01646.x     Document Type: Article

References (23)

1. Austin HA, Klippel JH, Balow JE, et al,. Therapy of lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N. Engl. J. Med. 1986; 314: 614-9. (Pubitemid 16132725)
2. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK,. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-7.
3. Chan TM, Li FK, Tang CS, et al,. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 2000; 343: 1156-62.
4. Chan TM, Tse KC, Tang CS, Lai KN, Li FK,. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-72. (Pubitemid 40559171)
5. Chan TM,. Preventing renal failure in patients with severe lupus nephritis. Kidney Int. 2005; 94: s116-119.
6. Chan TM, Tse KC, Tang CS, Mok MY, FK L, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 2005; 16: 1076-84. (Pubitemid 41710318)
7. Appel GB, Contreras G, Dooley MA, et al,. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 2009; 20: 1103-12.
8. Dooley MA, Jayne D, Ginzler EM, et al,. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 2011; 365: 1886-95.
9. Sola E, Lopez C, Gutierrez C, et al,. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: Clinical experience in the last 5 years. Transplant Proc. 2010; 42: 2859-60.
10. Dieckmann F, Campistol JM,. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol. Dial. Transplant. 2006; 21: 562-8. (Pubitemid 43372897)
11. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA,. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systemic review of the evidence. Transplantation 2006; 82: 1153-62. (Pubitemid 44748017)
12. Gabardi S, Baroletti SA,. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology and cardiology. Pharmacotherapy 2010; 30: 1044-56.
13. Eisen HJ, Tuzcu EM, Dorent R, et al,. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 2003; 349: 847-58. (Pubitemid 37025404)
14. Vitko S, Margreiter R, Weimar W, et al,. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. 2005; 5: 2521-30.
15. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
16. Warner LM, Adams LM, Sehgal SN,. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994; 37: 289-97. (Pubitemid 24065505)
17. Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, et al,. Prevention of murine lupus disease in (NZBxNZW) F1 mice by sirolimus treatment. Lupus 2007; 16: 775-81. (Pubitemid 350069789)
18. Lui SL, Yung S, Tsang R, et al,. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008; 17: 305-13. (Pubitemid 351655798)
19. Lui SL, Tsang R, Chan KW, et al,. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 2008; 23: 2768-76.
20. Campistol JM, Eris J, Oberbauer R, et al,. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 2006; 17: 581-9.
21. Kahan BD, Yakupoglu YK, Schoenberg L, et al,. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749-58. (Pubitemid 41443756)
22. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD,. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-9. (Pubitemid 41552882)
23. Branco F, Cavadas V, Osorio L, et al,. The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-centre renal transplantation cohort of 1816 patients. Transplant. Proc. 2011; 43: 137-41.